Supplementary Figures S4-S12 from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer

Supplementary Figure S4. Cell cycle distributions for veliparib, olaparib, and talazoparib, in A) HCC1143, B) MDAMB231, and C) HCC1806; Supplementary Figure S5. Cell cycle histograms for veliparib, olaparib, and talazoparib, in A) HCC1143, B) MDAMB231, and C) HCC1806 at selected concentrations; Supplementary Figure S6. Cleaved-PARP expression; Supplementary Figure S7. Representative EC50 dose-response curves of normalized percentage of cells positive for 53BP1 for veliparib, olaparib, and talazoparib in A) HCC1143, B) MDAMB231, C) HCC1806, D) HCC1395, and E) MDAMB436; Supplementary Figure S8. IC50 and EC50 values compiled for 8 breast cancer cell lines, for veliparib, olaparib, and talazoparib; Supplementary Figure S9. For each PARP inhibitor, correlations between IC50 values and A) EC50 values for % positive 53BP1, B) EC50 values for 53BP1 foci, C) EC50 values for % positive for cleaved-PARP; Supplementary Figure S10. Summary of Gene Set Enrichment Analysis (GSEA); Supplementary Figure S11. Enrichment plots after gene set enrichment analysis; Supplementary Figure S12. A) Presence of mutations in 63 gene-set in triple-negative breast cancer patients; B) Mutational frequency of 63 pathway enriched genes in triple-negative breast cancer (TNBC), ER-negative, ER-positive, basal, luminal B, and luminal A breast cancer subtypes.